Neil Versel is an Editor for Informatics, specializing in healthcare and precision medicine. With a focus on genomics, he has written for publications such as GenomeWeb, Precision Medicine Quarterly, and Healthcare IT News. Neil's expertise lies in covering advancements in technology, research, and policies that shape the field of healthcare informatics.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Neil Versel's coverage largely focuses on the intersection of healthcare, data, and genomics. His articles often feature private sector announcements and press releases. When reaching out to Neil, consider providing access to exclusive insights or expert commentary related to advancements in genomics, bioinformatics, or innovative technologies within the healthcare industry.
You may also want to highlight new developments in data analysis techniques relevant to genomics research as this aligns with his areas of interest. If your organization has significant news about its involvement in these fields or if you have experts who can offer unique perspectives on industry trends and challenges, it would be valuable information for Neil’s coverage.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Pictured: Hands exchanging money for medical science objects/Taylor Tieden for BioSpace
Pictured: U.S. and Chinese flags in concrete, broken in the middle/iStock, ffikretow
This is the first round in a series of cuts that will cost 75 people their jobs this year, according to a WARN notice. Employees in other states are affected as well.
Pictured: Illustration depicting large layoffs/iStock, Andrii Yalanskyi
Pictured: Judicial gavel and scales of justice/Courtesy iStock A federal judge in New Jersey on Monday ruled that the drug price negotiations
The Celularity CEO and founder tells BioSpace he believes that placenta-derived cells are the future of stem cell therapies to fight autoimmune disease, cancer, even aging.
Pictured: Collage of the U.S. Capitol, pills, money and justice statue/Taylor Tieden for BioSpace
Since the 2022 launch of ChatGPT, biopharma has poured money into this new form of artificial intelligence, but companies remain cautious with unproven technology.
By: Neil Versel
Pictured: AI robot holding biopharma-related items in hands/Taylor Tieden for BioSpace
After attacks on healthcare workers soared during the COVID-19 pandemic, providers have scrambled to address heightened violence in their workplaces.
(833) 317-6278 
